A Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer.
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of a combination of Avastin and
docetaxel following cyclophosphamide and doxorubicin, in patients with HER2 negative operable
breast cancer. Patients will receive 4 x 3 week cycles of chemotherapy with doxorubicin
(60mg/m2 iv on day 1 of each cycle) and cyclophosphamide (600mg/m2 iv on day 1 of each
cycle). They will then receive 4 x 3 week cycles of docetaxel (75mg/m2 on day 1 of each
cycle) in combination with Avastin (15mg/kg on day 1 of each cycle). The anticipated time on
study treatment is 3-12 months, and the target sample size is <100 individuals.